The FDA has approved the small‑molecule inhibitor pimicotinib (brand name Pimjetmi) for selected patients with symptomatic tenosynovial giant cell tumor (TGCT) who face a high surgical risk. This oral selective inhibitor of colony‑stimulating factor provides a non‑surgical treatment option for this rare benign soft‑tissue tumor.
Trending
- Russia Expels Moldovan Diplomat in Reciprocal Move Amid Drone Dispute
- FDA Approves New Oral Therapy for High‑Risk Tenosynovial Giant Cell Tumor
- Chargers Trade Daiyan Henley to Broncos for 2027 Fourth and 2028 Fifth‑Round Picks
- Hellebuyck Details Reasons Behind His Trade Request to the Jets Amid Career Uncertainty
- Howmet Aerospace: A Strategic Buy-the-Dip Opportunity Amid Market Overreaction
- Ra’am Chairman Claims Netanyahu Trusted Hamas’s Sinwar, Promises Testimony in October 7 Inquiry
- Singer Sombr Pleads with Concertgoer to Stop Flipping Him Off
- Syrian Airlines Reinstates Direct Berlin-Damascus Service After 14-Year Hiatus
The FDA has approved the small‑molecule inhibitor pimicotinib (brand name Pimjetmi) for selected patients with symptomatic tenosynovial giant cell tumor (TGCT) who face a high surgical risk. This oral selective inhibitor of colony‑stimulating factor provides a non‑surgical treatment option for this rare benign soft‑tissue tumor.